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Purpose: The cause of coagulopathic hemorrhage during thoracoabdominal aneurysm (TAA) 
repair has not been well defined in human studies. We investigated changes in the 
coagulation system associated with supraceliac versus infrarenal cross-clamping to address 
this critical issue. 
Methods: Blood levels of fibrinogen, the prothrombin fragment F1.2, D-dimer, and factors II, 
V, VII, VIII, IX, X, XI, and XII were analyzed in 19 patients with TAAs and four patients 
with abdominal ortic aneurysms (AAAs) at: (A) induction; (B) 30 minutes into supraceliac 
(TAA) or infrarenal (AAA) clamping; ( C ) 30 minutes after elease of supraceliac orinfrarenal 
clamps; and (D) immediately after surgery. Preoperative and intraoperative ariables, includ- 
ing but not limited to aneurysm type, pathologic findings, comorbid conditions, damp times, 
volume and timing of blood products, and clinical outcome, were prospectively recorded. 
Significance was determined by analysis of variance, Student's t test, and univariate linear 
regression. 
Results: Levels of fibrinogeu and factors II, V, VIII, VIII, IX, X, XI, and XII decreased 
(p < 0.05) at time B versus time A and returned to near baseline by time D. D-dimer and 
F1.2 increased starting at time B and reached significance (p < 0.05) by time D. Data 
points were compared for the TAA and AAA groups. Although AAA groups demon- 
strated atrend to factor activity reduction and increased fibrinolysis, the effect was much 
less pronounced than in TAA and did not approach significance. No correlation of 
coagulation change with damping time was present; however, visceral damping times 
were all less than 65 minutes (mean, 44 minutes). Blood and factor replacement was 
initiated after time B. Univariate regression analysis of factor level versus total blood 
replacement demonstrated a significant (p < 0.04) correlation between the reduction in 
the levels of factors II, V, VII, VIII, X, and XII, and the increase in the level of D-dimer 
at time B and subsequent total blood replacement. 
Conclusions: Thoracoabdominal aneurysm repair is associated with a reduction in dotting 
factor activity and an increase in fibrinolytic function, which occurs after placement of the 
supraceliac clamp. Explanations include visceral ischemia or a greater and longer ischemic 
tissue burden as the likely cause of coagulation alterations. Total blood replacement 
during TAA procedures was correlated to the degree o£ factor eduction and fibrinolysis 
at the time of visceral cross-clamping. An aggressive approach to early blood component 
replacement and to coagulation monitoring could lessen blood loss during TAA repair 
and avoid potentially disastrous bleeding complications. (J Vasc Surg 1996;24:936-45.) 
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Thoracoabdominal neurysm (TAA) repair re- 
mains a technically and physiologically challenging 
endeavor. Despite increasing reports from numerous 
institutions of significant improvement in results 
compared with historical controls, 1,2 TAA repair is 
still associated with significant morbidity and mortal- 
ity rates. Complications of  TAA repair that are in 
need of  improved methods of prevention haclude 
spinal cord ischemia nd coagulation defects. Hem- 
orrhage is responsible for deaths in 12% to 38% of 
patients in several series 3,4 and frequently takes the 
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form of a diffuse coagulopathy that is not necessarily 
associated with the technical surgical reasons for 
bleeding. There is a lmown incidence of consumptive 
coagulopathy associated with the unrepaired aneu- 
rysm 5 that may represent a pathologic event distinct 
from the bleeding seen during surgery in an individ- 
ual who was coagulation-normal before surgery. 
Previous research in animals has focused on intes- 
tinal or liver ischemia as the cause of coagulation 
defects, suggesting that prolongation of cross-clamp- 
ing above the celiac axis results in bacterial transuda- 
tion and resulting disseminated intravascular coagu- 
lation. 6 To date, however, no prospective study in the 
English literature has been designed to determine the 
nature of the coagulation defect during elective, un- 
complicated repair of TAAs. We theorized that coag- 
ulation derangements would be evident biochemi- 
cally before they manifest clinically and sought to 
support his theory with a prospective survey of co- 
agulation function in patients undergoing TAA repair 
at a single institution. 
MATERIALS AND METHODS 
Nineteen consecutive patients admitted for repair 
of a TAA were recruited into the study under the 
guidelines o f  the Massachusetts General Hospital 
Human Studies Committee. Preoperative variables 
that could potentially affect he outcome were noted, 
including tobacco use; familial aneurysm history; car- 
diac, renal, and pulmonary status; hypertension and 
diabetes; and lower-limb ischemia status using the 
SVS Ad Hoc Committee standards for risk factor 
assessment and leg ischemia. Anatomic and clinical 
variables included aneurysm type (I to IV by Craw- 
ford criteria); maximal diameter; the presence of ce- 
liac, superior mesenteric, or renal artery occlusive 
disease; total clamp tim e for visceral, renal, and infra- 
renal segments; and pathologic haracteristics of the 
aneurysm (degenerative, dissection, both). 
All TAA procedures were performed without any 
pump or shunting device, and heparin was not used. 
Coated Dacron grafts were used in all circumstances. 
The total blood product and fluid replacement, in- 
cluding autotransfused red blood cells, banked 
packed red blood cells, platelets, intraoperative crys- 
talloid, and intraoperative colloid volumes were 
noted along with the time of administration. 
The research design was intended to discern 
changes in coagulation function at different points of 
the procedure. To this end, blood was drawn for 
analysis at four time points: time A,I at induction; time 
B, 30 minutes after application of the proximal (su- 
praceliac): cross-damp; time C, 30 minutes after the 
release of proximal cross-clamp (visceral reperfusion); 
and time D, immediately after surgery. Blood was 
analyzed as follows. Factors II, V, VII, VIII, IX, X, 
XI, and XII were assayed by standard coagulation 
techniques with immunoabsorbed factor-deficient 
plasma. Fibrinogen was assayed by prothrombin- 
based method. D-dimer was measured by latex agglu- 
tination (Diagnostica Stago, Asnieres, France). Pro- 
thrombin fragment F1.2 was assayed by enzyme-linked 
immunosorbent assay (Organon Teknika, Durham, 
N.C.). 
To more clearly delineate the role of visceral 
ischemia as a result of supraceliac ross-clamping, 
four consecutive patients who underwent elective 
inffarenal abdominal aneurysm repair were subjected 
to the same analysis and data collection. For AAA 
repair, infrarenal cross-clamping, a transperitoneal 
approach, and systemic anticoagulation with intrave- 
nous heparin were used. Sampling times were: time 
A, at induction; time B, 30 minutes after application 
of the proximal (infrarenal) clamp; C, 30 minutes 
after release of the clamp (limb reperfusion); and D, 
immediately after surgery. All blood samples from 
patients with AAAs were treated with Hepzyme 
(IBEX-Dade, Baxter Corp. Miami, Fla.) to remove 
any influence ofheparin on the testing of the samples. 
Statistical significance was assessed with the Systat 
package (Microsoft) by analysis of variance, univari- 
ate linear regression, and Student's paired t test. 
RESULTS 
There were no deaths or bleeding complications 
in any of the patients. Comparison of starting values 
(time A) for all factors that were measured emon- 
strated no intrinsic difference when comparing pa- 
tients who had TAAs and those who had AAAs (Fig. 
1), and no evidence of a coagulation defect was 
present in any individual. Factors II, V, VII, VIII, IX, 
X, X2[, XII, fibrinogen, D-dimer, and F1.2 all demon- 
srrated significant (p < 0.05) differences in activity at 
time B in patients with TALk either when compared 
statistically with time A or when compared with the 
values at time B of patients who had AAAs. A gradual 
return to baseline was present in all these factors, as 
well, by time D. 
Fig. 2 demonstrates the findings at time B for 
coagulation factors. Thirty minutes after application 
of the proximal clamp, a significant reduction in 
factor activity is present in all factors when compared 
either with the control of the same patient at time A 
(before surgery) or with patients with AAAs at the 
same time B. Fig. 3 demonstrates the return to base- 
line for these factors at time D. 
Fibrinogen levels behaved in an identical fashion 
to clotting factors, with a decrease at time B to 200 
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Fig. 1. Factor levels at time A (baseline) for TAA and AAA. 
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Fig. 2. Factor levels at time B (30 minutes after application ofsupraceliac lamp) for TAA and 
AAA. Statistical comparison is made between TAA and AAA as well as with values at time A 
depicted in Fig. 1. 
mg/d l  (p < 0.05 when compared with 360 mg/d l  at 
time A) and a return to normal by time D. 
Fig. 4 demonstrates consistent findings for levels 
o f  D-dimer, an indicator offibrinolytic function, and 
F1.2, an indicator o f  prothrombin conversion to 
thrombin. The D-dimer level is expected to increase 
during active fibrinolysis, whereas the F1.2 level is 
expected to increase during active factor consump- 
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tion. In a pattern that is similar to that seen for 
coagulation factors and fibrinogen, the D-dimer and 
F1.2 levels are significantly elevated at time B in 
patients who have TAAs when compared either with 
TAA patients at time A, or with AAA patients at time 
B. Unlike coagulation factors, however, the levels of 
these fibrinolytic indicators do not return to normal 
by time D. 
A regression analysis was performed for all clot- 
ting and fibrinolytic factors versus total packed cells 
replaced and total fresh frozen plasma administered. 
No significant relationship was discerned for fresh 
frozen plasma. The total number of packed red blood 
cells administered, however, correlated strongly with 
the reduction in activity of factors II, V, VII, VIII, X, 
XII, and D-dimer. Regression values for these find- 
ings are given in Table I. A sample regression curve 
for factor V is given in Fig. 5. 
A representative pattern of clotting system activity 
is demonstrated in Fig. 6. Factor V begins at the same 
baseline for patients with TAAs as for patients with 
AAAs. After application of the proximal cross-clamp, 
however, asignificant reduction isobserved (time B), 
followed by a gradual return to baseline by comple- 
tion of the surgery (time D). Statistical significance 
(p < 0.05) in the difference between AAAs and TABs 
is only seen at time B. 
The mean cross-clamp time for the visceral seg- 
ment was 44 minutes, with a maximum of 65 min- 
utes, No correlation between cross-clamping of the 
FX FXI FXII 
levels at time D. 
visceral segment and coagulation abnormality could 
be discerned; however, the time variation was likely 
too narrow to distinguish its impact. No fresh frozen 
plasma or blood replacement was carried out before 
blood sampling at time B. 
DISCUSSION 
Perioperative coagulation events are difficult to 
assess because of the numerous variables that have an 
impact on the coagulation process. Our findings are 
qualitatively similar to those of a previous tudy in 
France of 33 consecutive patients who underwent 
thoracoabdominal repair. 7 In that study, significant 
decreases in factors II and V, protein C, fibrinogen, 
alpha 2 antiplasmin, and platelets were noted and 
were associated with a significant increase in cephalin 
and thrombin times. The series, however, had a 25% 
significant bleeding complication rate, and the find- 
ings were primarily noteworthy in the patients who 
were in this category. The possibility of surgical hem- 
orrhage and resultant factor dilution may complicate 
interpretation fthese data. Nonetheless, the pattern 
of consumption is similar to that seen in our 19 
elective patients without bleeding problems and sug- 
gests that factor diminution and fibrinolytic increase 
may be a continuum in patients who undergo su- 
praceliac ross-clamping. 
In studies of surgery for infrarenal aortic disease, a 
similar trend to early postoperative consumption is
present, with a return to normal, if not hypereoagu- 
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Fig. 4. A, D-dimer and F1.2 at time B for TAA and AAA. B, D-dimer and F1.2 at time D for 
TAA and AAA. 
lability, within 2 to 4 days. s The data in our study are 
similar in that a pattern of  coagulation derangement 
in AAA was observed that was qualitatively similar to 
that seen in patients with TAAs. In patients with 
AAAs, an elevation in fibrinolytic function and a 
decrease in dott ing factors occurred at time B and 
returned to normal by time D: but did not reach any 
statistical significance and was much less dramatic 
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Fig. 5. Sample regression curves for total packed red blood cells transfused versus reduction i  
factor V activity at time B for each patient. 
than that seen in TAA. This finding suggests that the 
addition of mesenteric schemia was responsible for 
the shift to more pronounced factor reduction and 
fibrinolytic activity. 
There are several possible interpretations of this 
finding. Bacterial translocation from intestinal isch- 
emia may have contributed, 6'9 as bacterial transloca- 
tion in other settings is also lmown to be associated 
with disseminated intravascular coagulation3 ° It is 
also possible that total ischemic tissue burden is re- 
sponsible because the supraceliac lamp necessarily 
renders not only the legs transiently hypoperfused, 
but also the entire gut. Recent evidence has linked 
disseminated intravascular coagulation to neutrophil 
activation and endothelial dysfunction,  which is 
consistent with the hypothesis that the greater isch- 
emic burden seen with complete aortic occlusion can 
account for the findings. 
Another possible explanation of the marked dif- 
ference between factor consumption and fibrinolytic 
activity observed between patients with AAAs and 
patients with TAAs is heparin administration. Cer- 
tainly, heparin can reduce the degree ofintravaseular 
coagulation, thereby blunting the effect seen in pa- 
tients with TAAs, who were all treated without hep- 
arin administration. The pattern of factor reduction 
and fibrinolytic activity, however, was similar in both 
groups, was exaggerated in patients with TAlks, and 
still supports the concept that aortic cross-clamping is 
associated with the coagulation derangement ob- 
stowed. Larger ischemic tissue beds, as would be seen 
with supracefiac cross-clamping, would lead to 
greater derangement, supporting the importance of 
Table I. Regression values for coagulation 
factor activity reducuon at rime B 
significantly correlated to total 
transfusion requirements 
Variable r 
Factor II 0.57 
Factor V 0.59 
Factor VII 0.48 
Facotr VIII 0.52 
Factor IX 0.49 
Factor X 0~49 
Factor XII 0.49 
D-dimer 0.49 
the visceral component to the coagulation derange- 
ment. In addition, normalization of the factors 
seemed to occur after the release of the visceral clamp 
and before the release of the infrarenal clamp, further 
emphasizing the contribution of visceral ischemia to 
the phenomena observed. 
Although there are numerous case reports of fi- 
brinolytic activation from AAA, 12-1a it is unclear 
whether these are sporadic events or a continuum of 
findings that can exist before surgery and therefore 
contribute to the events observed in this report. 
Mechanisms invoked have included extensive throm- 
bus formation 14 as well as the preoperative existence 
of focally concentrated platelet binding and tissue- 
type plasminogen activator presence and binding at 
the aneurvsm wall3 5 Our own data did not demon- 
strate any patients who had abnormal coagulation 
findings before undergoing surgery; however, there 
was a variety of factor acthdty within the normal range 
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that could be consistent with low levels of  consump- 
tion before resection of the involved aneurysms. No 
correlation of ancurysm size or thrombus load to 
preoperative factor levels and fibrinolytic activity was 
made because all preoperative measurements fell 
within the normal range. 
The findings of a more rapid return to baseline of 
clotting factors than fibrinolysis indicators after res- 
toration of visceral perfusion may be reflective of low 
levels of  fresh frozen plasma that were given after the 
release of the proximal cross-clamp. Given the ab- 
sence of any coagulation-related complications in this 
group of patients, however, this finding also suggests 
a strategy for the prevention of  the documented 
consumption of clotting factors that leads to clinically 
significant events. The current approach in our unit 
and other units 2 is the avoidance of heparin and the 
administration of  clotting factors primarily on the 
basis of clinical observation and blood turnover. No 
antifibrinolytic agents are administered without spe- 
cific signs ofdinical bleeding. Indeed, the low level of 
coagulopathy may bc protective against intravascular 
downstream thrombosis during repair of TAA with- 
out systemic anticoagulation. Nonetheless, a fine bal- 
ance exists that, if tipped in the direction of intravas- 
cular coagulation, may lead to a clinical bleeding 
disaster. Newer agents, such as aprotinin 16 may prove 
useful for further control f  the coagulation system 
during repair of TAA, and investigations are cur- 
rently in planning stages at our institution. All of  
these strategies remain speculative until a random- 
ized prospective study of the timing of factor admin- 
istration and antifibrinolytic agents is carried out. 
The data reported herein suggest hat in patients 
who undergo repair ofa TAA a biochemical intravas- 
cular coagulation exists after the supraccliac clamp is 
placed, with dotting factor normalization but initial 
persistence offibrinolytic dysfunction after perfusion 
is restored to the mesenteric and distal vessels. De- 
spite the biochemical findings, clinical coagulopathy 
did not occur. Given that the likely mechanism for 
the coagulation derangement observed was mesen- 
teric ischemia, it is likely that with longer operative 
and cross-clamp times, clinical manifestations of the 
coagulation derangement would have become appar- 
ent. By identifying the pattern of  coagulation dys- 
function in these elective cases, a strategy for the 
prevention of the idiosyncratic ntravascular coagula- 
tion caused either by cross-clamping orby  ex~/cerba- 
tion of a preexisting coagulopathic state can be 
evolved. In addition, in those patients in whom pro- 
longed cross-clamp times are either occurring or are 
anticipated, prophylactic earlier administration of 
clotting factors and inhibition of the fibrinolytic sys- 
tem may greatly enhance operative safety. 
The finding that the factor eduction measured at 
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t ime B correlated with packed red b lood  cell replace- 
ment  is strongly suggestive that these data can be 
used to evolve a strategy for the prevent ion o f  b lood 
loss dur ing the repair o f  TAAs. No  b lood or factor 
replacement was begun before t ime B in any o f  the 
patients tudied, so that the factor activity reduct ion 
and fibtinolytic activity seen at that point  is represen- 
tative o f  coagulat ion events as a result o f  the place- 
ment  o f  the supraceliac clamp. 
The total cost o f  the coagulat ion screen in each 
patient was close to $1,000. The final common path- 
way for intravascular coagulat ion in patients who 
have TAAs will remain to be t reatment  with factor 
replacement and fibrinolytic inhibit ion. The eco- 
nomic outcome of  rout ine factor and aprot inin ad- 
ministration, taldng into account the operative t ime 
and the cost o f  b lood  replacement,  will need to be 
examined in a prospective trial before it is determined 
whether  rout ine screening o f  these patients with a 
panel o f  coagulat ion testing makes economic sense. 
CONCLUSION 
TAA repair is associated with a reduct ion in clot- 
t ing factor activity and an increase in fibrinolytic 
funct ion that occurs after p lacement o f  the suprace- 
liac clamp, Biochemical intravascular coagulat ion 
does not  necessarily lead to clinical bleeding; how- 
ever, it offers a clear explanation o f  the pathophysio-  
logic mechanism of  b leeding events dur ing TAA re- 
pair in the absence o f  technical reasons for bleeding 
problems.  The impact o f  strategies to prevent ongo-  
ing  fibrinolysis and early aggressive clott ing factor 
replacement on outcome and cost remain to be pro-  
spectively determined.  
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DISCUSSION 
Dr. Mark Jackson (Washington, D.C.). Dr. Gertler 
and his colleagues have prospectively evaluated the causes 
of the coagulopathy that is frequently observed uring and 
after repair of TAAs. Nineteen consecutive patients were 
studied. All procedures were performed without he use of 
heparin or cardiofemoral bypass procedures. Their meth- 
ods include not only a descriptive analysis of the clotting 
factor alteration that occurs, which has been reported by 
others, but also, and quite importantly, an assessment of
the rule of fibrinolysis and thrombin generation. Their 
results how an acquired eficiency of all measured dotting 
factors 30 minutes after supraceliac cross-clamping. 
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This reduction was statistically significant compared 
with baseline values into the more modest factor eduction 
that was observed in a group of concurrently evaluated 
patients who underwent repair ofinfrarenal AAAs. Despite 
the observed clotting factor deficiency, no bleeding com- 
plications occurred. This can be attributed to the brief 
cross-clamp times of the aortic visceral segment, which 
averaged only 44 minutes, as well as to the accumulated 
institutional expertise in treating this challenging disorder. 
Of particular interest is that this study highlights the 
complexity and multifactorial nature of the changes in 
coagulation that are induced by TALk repair. The three 
salient observations are (1) the uniform deficiency of all 
clotting factors; (2) the generation of prothrombin frag- 
ment F1.2, indicating formation; and (3) the elevation of 
D-dimer, which indicates lysis of cross-linked fibrin. In 
their discussion, the authors have emphasized the added 
role of fibrinolysis in this setting and suggest he use of 
antifibrinolytic agents such as aprotinin in future clinical 
studies at their institution. Given that the generation of 
prothrombin fragment F1.2 indicates thrombin formation 
as another contributing element to this coagulopathy, the 
authors might consider, as an additional arm of such a 
study, a strategy that specifically addresses this part of the 
problem. The use of heparin, perhaps at a lower dose, 
would inhibit thrombin and thereby address the one ele- 
ment of this coagulopathy that the administration of anti- 
fbrinolytic agents and fresh frozen plasma do not. I wel- 
come the authors' comments regarding the use of heparin 
and an antifibrinolytic agent in this setting. 
Other observations of the study bear comment and 
clarification. Given the long half-lives of the depleted ot- 
ting factors, it is somewhat surprising that their levels 
rebounded so quickly and were noted to be about he same 
immediately after surgery as in the group of patients who 
underwent repair of an infrarenal ABft. How do the authors 
explain this finding? Could the postoperative correction be 
the result of intraoperative administration of fresh frozen 
plasma; or conversely, are the low intraoperative factor 
levels a reflection ofhemodilution by crystalloid? A descrip- 
tion of the administered fluid volumes would be helpful in 
this regard. Also, what were the changes in platelet counts, 
and were platelet transfusions necessary? 
I think we all share the authors' concern regarding the 
high cost of the routine, comprehensive coagulation 
screening in this study, for which one would have difficulty 
showing cost-effectiveness at $1,000 per patient, particu- 
larly because the baseline factor panel seemed to be uni- 
formly normal. The money, perhaps, would be better spent 
on fresh frozen plasma or on the empiric use ofheparin and 
aminocaproic acid in patients who are at risk for coagulopa- 
thy. 
Regarding the surgical technique, given that mesen- 
teric ischemia ppears to be a significant common denom- 
inator of this coagulopathy, would the authors now con- 
sider using cardiofemoral bypass to perfuse the lower aortic 
segment, particularly for type I and type II  TAAs, or for any 
proccdure where a prolonged cross-clamp time is antici- 
pated? 
Dr. Jonathan P. Gertler. The use of heparin as an 
antifibrinolytic agent opens up a can of worms. The use of 
heparin during these procedures has remained controver- 
sial, but we have in our unit chosen not to use heparin in 
our management scheme. 
The final common pathway that we are dealing with 
that may be damaging and uncorrectable is fibrinolysis. If  
dotting factor diminution and consumption leads to fibrin- 
split products, which ultimately lead again to an anticoag- 
ulant effect, the interruption of thrombin formation would 
be helpful potentially. However, I think that repletion of 
factors and the inhibition of fibrinolysis will achieve the 
same purpose clinically and avoid the potentially dangerous 
use ofheparin during this procedure, which already induces 
a coagulopathy, even at a low level. It may well be that it is 
somewhat protective to have minor coagulopathy during 
the execution of this procedure. We have not run into 
signifcant problems with leg thrombosis or organ vessel 
thrombosis during the execution of TAA repair procedures, 
and I cannot help but speculate that some degree of base- 
line coagulopathy contributes to the protective ffect of the 
way the procedure is performed. 
With regard to the dilution levels of crystalloid, as the 
patients receive much more crystalloid by time D than they 
did at time B, I would expect that dilution would be 
ongoing unless extensive replacement were taking place. I
have no doubts that the administration of fresh frozen 
plasma contributed to the rebound of the level of the 
factors, but I cannot invoke dilution as the source of the 
initial decrease of the factors. When you have evidence of 
consumption by the presence of F1.2, then you cannot 
invoke dilution as the explanation for the coagulopathy or
the biochemical coagulopathy that is taking place. 
Platelet counts did not decrease significantly in these 
patients and were not included in the data. The crystalloid 
volumes were not significantly different from those seen in 
the equivalent time period for infrarenal AAA repair. 
I would like to make one comment about screening. 
We saw some patients who had low-normal levels of certain 
of the factors. It could have been individual variation; it 
could have been a low-grade consumptive coagulopathy. In 
several of the patients who underwent cross-clamping and 
did not have administration fheparin, prolongation of the 
partial thromboplastin time occurred. Although none of 
those patients had clinical bleeding, this finding suggested 
that their baseline starting point was lower and that they 
were more easily tipped over the balance into at least a 
biochemical coagulopathy. If that is the case, it may take 
only one or two of those patients who have excessive 
bleeding, excessive intensive care unit stays, and prolonged 
operative time to account for the cost incurred with 20 
coagulation panels. 
Cardiofemoral bypass adds little, I think, to our total 
operative time. The proximal anastomosis goes very 
quickly, and I don't think it would significantly shorten or 
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protect he mesenteric segment given the way the cases are 
done. 
Dr. Richard M. Green  (Rochester, N.Y.). We per- 
formed a similar study, and it will be reported in June at the 
national meetings (SVS/ISCVS-NA) with a little different 
conclusion. 
Our data show that after 20 minutes of supraceliac 
aortic clamping there is an induced state of primary fibri- 
nolysis. The term "consumptive coagulopathy" is a bit 
sloppy. Total tissue-type plasminogen activator ises, but 
that is not the real problem. The most significant finding is 
that the production of plasminogen activator inhibitor-I, 
which is a natural inhibitor of tissue-type plasminogen 
activator, is reduced. For a short period of time there is an 
imbalance between the inhibitors of tissue-type plasmino- 
gen activator and the elevated tissue-type plasminogen 
activator, and a state of primary fibrinolysis occurs. 
We think that this is an analogous situation to the 
anahepatic phase of orthotopic liver transplantation. 
Whether this is a result of superior mesenteric artery or 
celiac artery hypoperfusion is not clear, but the target organ 
in our findings is the liver, and this is corroborated by 
simultaneous increases in the values indicative of hepato- 
cellular dysfunction. This has prompted us in our thoraco- 
abdominal cases to perfuse the arteries with an octopus 
setup to a Biomedicus pump. This should eliminate the 
primary fibrinolytic state. I wondered with these data, re 
you going to continue to use the "clamp and sew" tech- 
nique, or are you going to start using perfusion? 
Dr. Gertler. I think that it is unlikely that we will start 
to use perfusion because we have been happy with the 
approach we have been using with regard to the results that 
we have obtained. I agree with you fully that the hepatic 
ischemia is probably much more prominent han small- 
bowel ischemia, and we have certainly seen that clinically in 
patients who have had celiac artery problems. 
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